These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 16182816)
21. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910 [TBL] [Abstract][Full Text] [Related]
22. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Pescovitz MD; Nezakatgoo N; Lorber MI; Nashan B; Tedesco-Silva H; Kasiske BL; de la Cruz FJ; Russ G; Campistol J; Keown PA; Transplantation; 2009 Oct; 88(8):1010-8. PubMed ID: 19855247 [TBL] [Abstract][Full Text] [Related]
23. Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors. Lisik W; Kahan BD Transplant Proc; 2006; 38(1):69-73. PubMed ID: 16504667 [TBL] [Abstract][Full Text] [Related]
24. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA; Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914 [TBL] [Abstract][Full Text] [Related]
25. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386 [TBL] [Abstract][Full Text] [Related]
26. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated. Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060 [TBL] [Abstract][Full Text] [Related]
27. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Bunnapradist S; Daswani A; Takemoto SK Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. Chueh SC; Wang SM; Lai MK; Chen J Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745 [TBL] [Abstract][Full Text] [Related]
29. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. Saber LT; Ikeda MY; Almeida JM Transplant Proc; 2007 Dec; 39(10):3098-100. PubMed ID: 18089330 [TBL] [Abstract][Full Text] [Related]
30. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656 [TBL] [Abstract][Full Text] [Related]
31. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558 [TBL] [Abstract][Full Text] [Related]
33. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report. Pascual J; Fernández AM; Marcén R; Ortuño J Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857 [TBL] [Abstract][Full Text] [Related]
34. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Pliszczynski J; Kahan BD Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822 [TBL] [Abstract][Full Text] [Related]
35. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy. Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307 [TBL] [Abstract][Full Text] [Related]
36. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
37. Marked erythrocyte microcytosis under primary immunosuppression with sirolimus. Kim MJ; Mayr M; Pechula M; Steiger J; Dickenmann M Transpl Int; 2006 Jan; 19(1):12-8. PubMed ID: 16359372 [TBL] [Abstract][Full Text] [Related]
38. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400 [TBL] [Abstract][Full Text] [Related]
39. New approaches to de novo immunosuppression and steroid elimination. Lebranchu Y Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295 [TBL] [Abstract][Full Text] [Related]
40. Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients. Chang HR; Lin CC; Lian JD Transplant Proc; 2007 Jun; 39(5):1520-2. PubMed ID: 17580178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]